Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell technology. This new patent extends protection of Anixa’s CAR-T technology to 2045. The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa’s innovative CAR-T approach. Anixa’s CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This newly issued patent builds on Anixa’s growing portfolio of CAR-T intellectual property, collectively designed to protect the platform’s use across multiple tumor types. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa’s CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating
- Anixa plans to begin Phase 2 of breast cancer vaccine trial
- Anixa receives Notice of Allowance for breast cancer technology patent in Canada
- Anixa Biosciences Receives Buy Rating Amidst Strong Patent Portfolio and Promising Vaccine Trials
- Anixa Biosciences awarded new U.S. patent for breast cancer technology